Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Shah T, et al. PMID 39985508
Related Questions
Are there any trans-cathter options available in a patient s/p m-TEER with residual severe MR with high surgical risk who has worsening heart failure symptoms?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
What would be your approach for the management of asymptomatic, severe AS with a peak velocity of 5 m/s in an otherwise physically active patient in their mid-90s without significant co-morbidities?
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
What is your approach to the management of severe tricuspid regurgitation secondary to endocarditis with the presence of an RV pacemaker lead in place?
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
